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Inhibitory role of Smad3 in 
epithelial–myofibroblast transition
Masszi et al., J Cell Biol 2010; 188: 383–399; doi:10.1083/jcb.200906155
Epithelial–mesenchymal transition (EMT) is a dramatic change in 
phenotype characterized by loss of epithelial features such as apico-
basal polarity and development of mesenchymal features such as 
increased mobility and contractility. EMT plays a critical role dur-
ing embryonic development and in adult life during wound healing. 
EMT can lead to generation of mesenchymal cells and to activation 
of a myogenic program that generates myofibroblasts, which are 
mesenchymal cells expressing α-smooth muscle actin (SMA). SMA 
expression in the epithelium, that is, epithelial-to-myofibroblast 
transition (EMyT), is also a critical process in pathological organ 
fibrosis, a condition prominent in many renal diseases. In the kid-
ney and other organs, tissue accumulation of myofibroblasts and 
the level of SMA expression have long been known to correlate 
closely with the severity of fibrosis and disease. Although scientists 
debate the exact origin of myofibroblasts in various models of organ 
fibrosis, EMyT is likely an important component of many fibrotic 
diseases. Despite their importance, the molecular mechanisms that 
turn on and regulate the myogenic program (SMA expression) in 
epithelial cells are poorly understood. Previous studies showed 
that for kidney epithelial cells to express SMA, an abnormality in 
the intercellular contacts (for example, their uncoupling by low-
calcium medium or direct wounding) plus transforming growth 
factor-β1 (TGF-β1) was required, suggesting a two-hit model of 
EMyT. Additional research found that contact injury stimulated 
the SMA promoter by translocating into the nucleus the myo-
cardin-related transcription factor (MRTF), a recently described 
myogenic transcriptional coactivator. However, injury-induced 
MRTF translocation alone was insufficient for SMA expression, 
as the process also required TGF-β. Because the SMA promoter 
harbors both MRTF-responsive sequences and TGF-β-responsive 
Smad-binding elements, Masszi et al. postulated that the myogenic 
program in epithelial cells may be initiated by a synergy between 
MRTF and Smad3. They found that the synergy between injury 
and TGF-β exclusively required a critical element in the SMA 
promoter by which Smad3 interfered with the stimulatory effect 
of MRTF. Smad3 inhibited MRTF-driven activation of the SMA 
promoter, and Smad3 silencing rendered injury alone sufficient to 
induce SMA expression (Figure). Interestingly, the authors found 
that myogenic stimuli induced dramatic loss in Smad3 protein 
through both transcriptional and post-transcriptional mechanisms, 
and that this preceded expression of SMA. Thus, under the two-hit 
model, degradation of Smad3 liberates the myogenic program. The 
study identifies Smad3 as an inhibitor of the myogenic program in 
epithelia.
Juan Oliver
Rho exchange factor Arhgef1 
mediates the effects of angiotensin II 
on blood pressure
Guilluy et al., Nat Med 2010; 16: 183–190; doi:10.1038/nm.2079
RhoA is a member of the Rho family of small guanosine 
5′-triphosphate (GTP)-binding proteins, which use Rho kinases 
as downstream effectors. These enzymes mediate multiple critical 
cellular functions, such as cell shape, motility, proliferation, and gene 
expression. RhoA and Rho kinase activities have been implicated in 
the regulation of vascular tone and cardiovascular disease, and over-
activation of RhoA and its kinases appears to be important in the 
pathogenesis of several forms of hypertension. RhoA is a molecular 
switch that cycles between an inactive, guanosine 5′-diphosphate 
(GDP)-bound form and an active, GTP-bound form, which acti-
vates its effector Rho kinase. In turn, the kinase phosphorylates a 
subunit of the myosin phosphatase, thus inhibiting its enzymatic 
activity. This inhibition results in Ca2+ sensitization of contractile 
proteins, which maintains the tonic component of vascular smooth 
muscle contraction. Interestingly, inhibition of the angiotensin 1 
receptor reduced the upregulation of RhoA and Rho kinase activity 
in hypertensive rats, and in vivo long-term infusion of angiotensin II 
increased the activity of RhoA and Rho kinase in arteries, suggesting 
a role for angiotensin II-induced activation of RhoA and Rho kinase 
in the pathogenesis of hypertension. These observations led Guilluy 
et al. to postulate that inhibition of RhoA activation could reduce 
the development of angiotensin II-dependent hypertension. Activa-
tion of Rho proteins is mediated by guanine nucleotide exchange 
factors (GEFs), which exchange GDP for GTP. These GEFs are, 
in turn, activated by upstream signals, such as G protein-coupled 
receptors, tyrosine kinase receptors, and adhesion receptors. Using 
a proteomics approach, the researchers first identified Arhgef1 as 
the GEF that specifically mediates angiotensin II-dependent RhoA 
activation and found that angiotensin II activates Arhgef1 through 
a previously unknown mechanism in which Jak2 phosphorylates 
Tyr738 of Arhgef1. Importantly, by generating mice lacking Arhgef1 
specifically in smooth muscle cells, the authors found that these 
animals were resistant to angiotensin II-dependent hypertension 
Reduced Smad3 expression robustly facilitated α-smooth muscle actin 
(SMA) promoter activity during disruption of intercellular contacts. 
Disruption of intercellular contacts by low-calcium media (LCM) had no 
effect on SMA mRNA when cells were treated with non-related siRNA 
(NR si, left). However, Smad3 silencing by siRNA strongly potentiated SMA 
mRNA expression (right).
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(Figure) but had normal blood pressure regulation. These results 
show that control of RhoA signaling through Arhgef1 is central to 
the development of angiotensin II-mediated hypertension and iden-
tify Arhgef1 as a potential target for antihypertensive therapy.
Juan Oliver
BASP1 promotes apoptosis in 
diabetic nephropathy
Sanchez-Niño et al., J Am Soc Nephrol advance online publication, 28 January 
2010, doi:10.1681/ASN.2009020227
Diabetic nephropathy remains the single most common reason for 
end-stage renal disease in the Western world. During the past dec-
ade, the potential role of cell loss due to apoptosis in the progression 
of renal disease, especially diabetic nephropathy, has attracted con-
siderable interest. The diabetic milieu is known to induce apoptosis 
in various end-organ systems and thereby contribute to the grad-
ual loss of organ function, especially in the kidney. Apoptosis has 
been detected in podocytes and tubular epithelial, endothelial, and 
interstitial cells in experimental diabetic renal disease and in renal 
biopsy samples from patients with diabetic nephropathy. Cell death 
via apoptosis is an active response to an altered microenvironment 
and is characterized by the activation of specific intracellular path-
ways. Sanchez-Niño et al. approached this problem by combining a 
functional genomic screen for complementary DNAs (cDNAs) that 
induce apoptosis in vitro with transcriptional profiling of renal biop-
sies from patients with diabetic nephropathy. Twelve of the 138 full-
length cDNAs that induced cell death in human embryonic kidney 
cells matched upregulated mRNA transcripts in tissue from human 
diabetic nephropathy. Confirmatory screens identified induction of 
a potentially novel apoptosis-related gene, BASP1, in tubular cross-
sections of human diabetic nephropathy tissue. In vitro, apoptosis-
inducing conditions such as serum deprivation, high concentrations 
of glucose, and proinflammatory cytokines increased BASP1 mRNA 
and protein in human tubular epithelial cells. In normal cells, BASP1 
localized to the cytoplasm, but in apoptotic cells, it colocalized 
with actin in the periphery. Overexpression of BASP1 induced cell 
death with features of apoptosis. Conversely, small interfering RNA 
(siRNA)-mediated knockdown of BASP1 protected tubular cells 
from apoptosis. Thus the combined functional genomics approach 
identified BASP1 as a novel proapoptotic factor in diabetic nephrop-
athy, attesting to the strength of such genetic approaches to discover 
novel genes involved in disease progression.
Eventually a more complete picture of all factors and genes 
involved in the development and progression of diabetic nephropa-
thy should help in sorting out the major pathways involved and, 
hopefully, identify future targets for therapeutic intervention.
Detlef Schlöndorff
Stent graft versus balloon 
angioplasty for failing  
dialysis-access grafts
Haskal et al., N Engl J Med 2010; 362: 494–503
This prospective, multicenter trial for the treatment of hemo-
dynamically significant venous anastomotic stenoses in 
arteriovenous grafts randomized patients with end-stage renal 
disease receiving dialysis through a failing, but non-thrombosed, 
prosthetic arteriovenous graft to one of two arms. Patients under-
went either standard-of-care balloon angioplasty of their stenoses 
or implantation of an expanded polytetrafluoroethylene stent graft. 
This phase II study by Haskal et al. sought to demonstrate that treat-
ment using a stent graft is not inferior to treatment with balloon 
angioplasty alone with respect to the 6-month primary patency of 
a stenotic venous anastomosis in the treatment area. Patients were 
eligible if they had angiographic evidence of one or more stenoses 
that was greater than 50% at the graft–vein anastomosis. The arte-
riovenous graft needed to have been implanted more than 30 days 
before enrollment and to have had at least one successful dialysis 
session use. Ninety-seven subjects were randomized to undergo 
implantation of the investigational stent graft. Ninety-three were 
randomized to undergo balloon angioplasty only. A total of 125 
stents were placed in the 97 subjects randomized to the investiga-
tional arm. All procedures in both arms resulted in hemodynamic 
success, defined as a residual stenosis less than 30%. A similar 
proportion of subjects in both arms were able to resume normal 
dialysis using the arteriovenous graft for at least one session. More 
subjects in the stent group had an anatomic success (94% versus 
73%), defined as a post-procedure stenosis less than 30% at the nar-
rowest point. Primary patency of the treatment area and the dialysis 
circuit was similar between the two arms at 2 months. However, 
the investigators noted a difference at 6 months. Although the pro-
portion of subjects in each arm experiencing primary patency had 
fallen, it was still greater in the interventional stent group (51% 
versus 23% for treatment area patency, and 38% versus 20% for 
access circuit patency) than in the balloon angioplasty group.
Improving vascular-access outcomes requires a multipronged 
approach of prevention as well as treatment of anastomotic 
strictures. Given these results and the paucity of data comparing 
treatment strategies, stenting represents a promising area for 
further study. Although only phase II data, the results do appear 
positive and support moving the science ahead to improve 
outcomes for our patients.
Lynda Szczech
Systolic blood pressure in smooth muscle (SM)-Arhgef1-floxed and 
SM-Arhgef1-knockout (KO) mice chronically treated with angiotensin II 
(Ang II).
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